All solid tumours require a vascular supply in order to progress. Although the ability to
induce angiogenesis (new blood vessel growth) has long been regarded as essential to this …

Compelling evidence have demonstrated that bulk tumors can arise from a unique subset of
cells commonly termed “cancer stem cells” that has been proposed to be a strong driving …

Patients with glioblastoma (GBM) have a universally poor prognosis and are in urgent need
of effective treatment strategies. Recent advances in sequencing techniques unraveled the …

Malignant astrocytic gliomas such as glioblastoma are the most common and lethal
intracranial tumors. These cancers exhibit a relentless malignant progression characterized …

Patient-based cancer models are essential tools for studying tumor biology and for the
assessment of drug responses in a translational context. We report the establishment a large …

Bevacizumab, an antibody against vascular endothelial growth factor (VEGF), is a
promising, yet controversial, drug in human glioblastoma treatment (GBM). Its effects on …

Despite aggressive surgery, radiotherapy and chemotherapy, malignant gliomas remain
uniformly fatal. To progress, these tumours stimulate the formation of new blood vessels …

Background: Liver metastases present with distinct histopathological growth patterns
(HGPs), including the desmoplastic, pushing and replacement HGPs and two rarer HGPs …

Although vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2) is traditionally
regarded as an endothelial cell protein, evidence suggests that VEGFRs may be expressed …

Glioblastomas (GBMs), the most common primary brain tumor in adults, are characterized by
resistance to chemotherapy and radiotherapy. One of the defining characteristics of GBM is …